Background: Visual impairment in diabetic retinopathy (DR) due to diabetic macular edema (DME) is common and disabling for increasing diabetic population all over the world.
Hind A. Mahdi
doaj
Effect of panretinal photocoagulation versus intravitreal bevacizumab injection on optic disc microcirculation in patients with diabetic retinopathy. [PDF]
Khojasteh H +8 more
europepmc +1 more source
Real-world outcomes of intravitreal bevacizumab treat-and-extend for cystoid macular oedema secondary to central retinal vein occlusion. [PDF]
Gildea D, Tang B, Baily C, Ryan A.
europepmc +1 more source
Factors Affecting Compliance and Visual Outcomes in Patients Receiving Intravitreal Bevacizumab Injections. [PDF]
Radhakrishnan O +4 more
europepmc +1 more source
The Risk of Non-arteritic Ischemic Optic Neuropathy Post-intravitreal Bevacizumab Injection. [PDF]
Fugara NA +6 more
europepmc +1 more source
The treatment of diabetic macular edema with intravitreal bevacizumab in users of the Brazilian public health system. [PDF]
Ibrahim LF +4 more
europepmc +1 more source
Choroidal Response to Intravitreal Bevacizumab Injections in Treatment-Naïve Macular Neovascularization Secondary to Chronic Central Serous Chorioretinopathy. [PDF]
Rabinovitch D +9 more
europepmc +1 more source
Evaluating the causes of retinopathy of prematurity relapse following intravitreal bevacizumab injection. [PDF]
Milani AE +5 more
europepmc +1 more source
Trabeculectomy with concurrent intravitreal bevacizumab in neovascular glaucoma. [PDF]
Khan SM, Rao A.
europepmc +1 more source

